EXM — Exmceuticals Income Statement
0.000.00%
HealthcareSpeculativeMicro Cap
Annual income statement for Exmceuticals, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2016 June 30th | 2017 June 30th | 2018 June 30th | 2019 June 30th | 2020 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.496 | 0.152 | 0.327 | 9.76 | 9.34 |
| Operating Profit | -0.496 | -0.152 | -0.327 | -9.76 | -9.34 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.496 | -0.154 | -0.335 | -9.83 | -9.93 |
| Net Income After Taxes | -0.496 | -0.154 | -0.335 | -9.83 | -9.93 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.496 | -0.154 | -0.335 | -9.83 | -9.25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.496 | -0.154 | -0.335 | -9.83 | -9.25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.026 | -0.011 | -0.015 | -0.217 | -0.215 |
| Dividends per Share |